Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.65
Ask: 1.75
Change: 0.05 (3.03%)
Spread: 0.10 (6.061%)
Open: 1.65
High: 1.95
Low: 1.65
Prev. Close: 1.65
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: iEnergizer to depart; Unbound for sale

Fri, 19th May 2023 10:15

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

iEnergizer PLC, up 24% at 67 pence, 12-month range 29.5p-526p. The Noida, India-based IT service management firm says its shares will stop trading on AIM on Wednesday. In April, it said it was seeking cancellation, stating that staying on the stock exchange was "unlikely to provide the company with significantly wider access to capital", adding that the cost and legal implications of maintaining its admission to trading on AIM were "disproportionate" to the benefits.

----------

Genedrive PLC, up 16% at 23.70p, 12-month range 8.00p-48.86p. The point-of-care molecular diagnostics firm says the UK National Institute for Health & Care Excellence recommends in draft guidance that CYP2C19 genotyping should be used before clopidogrel administration in managing ischemic stroke patients. "Screening patients to assess their clopidogrel resistance status allows for alternative treatments and better clinical outcomes," the company explains. The NICE Committee included the firm's CYP2C19 ID test in its review. Genedrive notes the test is still in development. Awaits the UKCA marking on the test prior to NICE's final report, currently scheduled for October.

----------

AIM - LOSERS

----------

Velocys PLC, down 28% at 2.41p, 12-month range 2.20p-7.30p. The sustainable fuels technology company says the books are covered at around GBP6 million for its placing and retail offer. The books remain open. The fundraise was announced after the market close on Thursday, with an issue price of 2.5p for each. The price is a 26% discount to Thursday's closing price of 3.4p. Velocys had voiced concerns over its ability to continue as a going concern. It aims to raise at least GBP32 million by the placing, retail offer, open offer, as well as a conditional issuance of convertible loan notes to Carbon Direct Capital and potential further issuances of convertible loan notes and/or new ordinary shares to investors other than Carbon Direct Capital.

----------

Unbound Group PLC, down 23% at 2.51p, 12-month range 2.51p-35.94p. The stock reaches a 12-month low as the firm launches a strategic review, including a formal sales process. Unbound is the parent company for a retail group selling a range of brands focused on the 55+ demographic, including Hotter Shoes. The review is to explore its strategic options, and could include a full sale of the company. Unbound warns a temporary working capital shortfall could arise in September and October this year. It continues to work with its advisers and banking partners to raise additional funds or refinance its current facilities.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
31 Aug 2021 12:05

Genedrive to seek CE mark clearance for MT-RNR1 assay

(Sharecast News) - Molecular diagnostics company Genedrive said on Tuesday that it will soon launch its MT-RNR1 assay, used for the detection of antibiotic-induced hearing loss in newborns.

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
1 Jul 2021 09:52

Genedrive makes progress with Covid-19 test development

(Sharecast News) - Molecular diagnostics company Genedrive updated the market on the development of its 'COV19-ID Kit', a rapid point-of-care molecular test for SARS-CoV-2 detection designed for its 'Genedrive instrument', on Thursday.

Read more
25 Jun 2021 14:39

IN BRIEF: Genedrive receives Indian import license for Covid test kit

IN BRIEF: Genedrive receives Indian import license for Covid test kit

Read more
30 Apr 2021 13:16

Genedrive Covid-19 test formally approved in India

(Sharecast News) - Molecular diagnostics company Genedrive announced on Friday that the 'Genedrive 96' SARS-CoV-2 kit had been formally approved by the Indian Council of Medical Research (ICMR).

Read more
30 Apr 2021 10:51

Genedrive shares surge after Covid test approved by Indian regulator

Genedrive shares surge after Covid test approved by Indian regulator

Read more
30 Apr 2021 10:40

AIM WINNERS & LOSERS: Hurricane Energy warns of "significant dilution"

AIM WINNERS & LOSERS: Hurricane Energy warns of "significant dilution"

Read more
23 Apr 2021 10:02

Genedrive says study shows kit is effective at diagnosing Hepatitis C

Genedrive says study shows kit is effective at diagnosing Hepatitis C

Read more
19 Apr 2021 14:10

UPDATE: Yourgene wins further national framework contract award

UPDATE: Yourgene wins further national framework contract award

Read more
19 Apr 2021 12:46

IN BRIEF: Genedrive included in Public Health England framework

IN BRIEF: Genedrive included in Public Health England framework

Read more
19 Apr 2021 12:07

Genedrive appointed to PHE microbiology supply framework

(Sharecast News) - Molecular diagnostics company Genedrive has been successful with its tender to Public Health England (PHE) under Lot 1 of the National Microbiology Framework for diagnostic goods and services, it announced on Monday.

Read more
19 Apr 2021 11:44

Yourgene wins national contract award for Covid-19 testing services

Yourgene wins national contract award for Covid-19 testing services

Read more
19 Apr 2021 11:32

AIM WINNERS & LOSERS: Pantheon falls after Alaska drilling results

AIM WINNERS & LOSERS: Pantheon falls after Alaska drilling results

Read more
25 Mar 2021 14:49

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

TRADING UPDATES: Safestyle in strong start to 2021; Tandem ups payout

Read more
25 Mar 2021 11:28

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.